source
- Bristol Myers faces pivotal year as Q1 earnings season beginsThe weekly Endpoints newsletter for the last week of April highlighted that several pharmaceutical companies released their first-quarter earnings. Among them, Bristol Myers was singled out as bei…
- Bristol Myers shows modest revenue rise, Biogen beats forecasts, Regeneron outlook remains uncertainBioPharma Dive highlighted the latest quarterly earnings from three major biotech firms, noting how investors are interpreting the results. Bristol Myers Squibb reported $11.5 billion in revenue f…